Analisis Parameter Perencanaan dan Evaluasi Kurva Dose Volume Histogram Pasien Kanker Glioblastoma Berdasarkan Treatment Planning System
DOI:
https://doi.org/10.25077/jfu.13.5.617-623.2024Keywords:
Conformity Index, Glioblastoma Multiforme, Homogeneity IndexAbstract
Glioblastoma cancer (GBM) is a malignant brain tumour that develops aggressively and has a short life expectancy so it requires appropriate treatment for its treatment. The purpose of this study was to determine a more effective treatment technique in GBM cancer patients by comparing Three Dimension Conformal Radiation Therapy (3D-CRT) and Intensity Modulated Radiation Therapy (IMRT) irradiation techniques based on the parameters of Conformity Index (CI), Homogeneity Index (HI), maximum dose and Normal Tissue Integral Dose (NTID) of healthy tissue, as well as Dose Volume Histogram (DVH) curves obtained from the Treatment Planning System (TPS). This study used 10 GBM cancer patient data using a 6 MV photon beam and a total dose of 60 Gy. The data used are the volume of cancer when 95% of the radiation dose is given, the total volume of cancer, the radiation dose at 2%, 50%, 98%, the average dose and the volume of Organ at Risk (OAR). The results showed that the CI value for 3DCRT technique was 0.87-1.00 and IMRT technique was 0.92-0.98. HI value for 3DCRT technique is 0.02-0.07 and IMRT technique is 0.01-0.05. The percentage of the maximum dose value for the 3D-CRT technique is between 104.72% to 108.95% while the IMRT technique is between 98.40% to 108.60%. The NTID values obtained in both techniques did not exceed the established dose limits and were in accordance with the Radiation Therapy Oncology Group (RTOG) 0825 and 0615. IMRT technique is more effective than 3DCRT technique for GBM cancer patients based on CI, HI and maximum dose values.
References
BAPETEN. (2013). Peraturan Kepala Badan Pengawas Tenaga Nuklir Nomor 3 Tahun 2013 tentang Keselamatan Radiasi Dalam Penggunaan Radioterapi. https://jdih.bapeten.go.id. Diakses Juni 2023.
Das Majumdar, S. K., Amritt, A., Dhar, S. S., Barik, S., Beura, S. S., Mishra, T., Muduly, D. K., Dash, A., & Parida, D. K. (2022). A Dosimetric Study Comparing 3D-CRT vs. IMRT vs. VMAT in Left-Sided Breast Cancer Patients After Mastectomy at a Tertiary Care Centre in Eastern India. Cureus, 14(3).
Davis, C. P. (2018). Kanker Otak: Gejala, Penyebab, Diagnosis dan Pengobatan. https://www.itokindo.org. Diakses Juli 2023.
Dian Savitri, Y., Sutapa, G. N., Balik Sudarsana, I. W., & Irhas, R. (2022). Radioterapi Linac Energi 6 MV Terhadap Kanker Serviks Pada Organ Rektum Menggunakan Teknik 3DCRT dan IMRT Di RSUP Sanglah Denpasar. Kappa Journal, 6(1), 7-14.
Effina, A., Milvita, D., & Ilyas, M. (2022). Distribusi Dosis Radiasi Foton pada Treatment Planning System Menggunakan Teknik 3DCRTdan IMRT untuk Terapi Kanker Serviks. Jurnal Fisika Unand, 11(1), 126-130.
GLOBOCAN (Global Cancer Observatory) Homepage. (2020). Cancer In Indonesian. https://gco.iarc.fr. Diakses juli 2023.
Husni, M., Shafii, M. A., Adrial, R., & Ilyas, M. (2021). Analisis Perbandingan Nilai Conformity Index dan Homogeneity Index pada Teknik 3D-CRT dan IMRT pada Kasus Kanker Payudara Berdasarkan Hasil TPS di RS UNAND. Jurnal Fisika Unand, 10(4), 511-517.
ICRU Report 83. (2010). Prescribing, Recording and Reporting Photon Beam Intensity Modulated Radiation Therapy (IMRT). The International Commission on Radiation Units and Measurements. USA.
ICRU Report 62. (1999). Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). The International Commission on Radiation Units and Measurements. USA.
Low, J. T., Ostrom, Q. T., Cioffi, G., Neff, C., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022). Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neuro-Oncology Practice, 9(3), 165-182.
RTOG 0615. (2011). A Phase Ii Study Of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3d-Crt) Or Intensity-Modulated Radiation Therapy (Imrt) + Bevacizumab (Bv) For Locally Or Regionally Advanced Nasop. Radiation Therapy Oncology Group. USA.
RTOG 0825. (2010). Phase Iii Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Pati. Radiation Therapy Oncology Group. USA.
Tan, A. C., Ashley, D. M., Lopez, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020). Management of glioblastoma: State of the art and future directions. CA: A Cancer Journal for Clinicians, 70(4), 299-312.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Intan Pratiwi Riani, Rico Adrial, winny Rahmadani Papesta, Hanifa Shafira
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Please find the rights and licenses in JFU (Jurnal Fisika Unand).
1. License
The non-commercial use of the article will be governed by the Creative Commons Attribution license as currently displayed on Creative Commons Attribution-NonCommercial 4.0 International License.
2. Authors Warranties
The author warrants that the article is original, written by stated author(s), has not been published before, contains no unlawful statements, does not infringe the rights of others, is subject to copyright that is vested exclusively in the author and free of any third party rights, and that any necessary written permissions to quote from other sources have been obtained by the author(s).
3. User Rights
JFU's spirit is to disseminate articles published are as free as possible. Under the Creative Commons license, JFU permits users to copy, distribute, display, and perform the work for non-commercial purposes only. Users will also need to attribute authors and JFU on distributing works in the journal.
4. Rights of Authors
Authors retain the following rights:
- Copyright, and other proprietary rights relating to the article, such as patent rights,
- The right to use the substance of the article in future own works, including lectures and books,
- The right to reproduce the article for own purposes, provided the copies are not offered for sale,
- The right to self-archive the article.
5. Co-Authorship
If the article was jointly prepared by other authors, the signatory of this form warrants that he/she has been authorized by all co-authors to sign this agreement on their behalf, and agrees to inform his/her co-authors of the terms of this agreement.
6. Termination
This agreement can be terminated by the author or JFU upon two months notice where the other party has materially breached this agreement and failed to remedy such breach within a month of being given the terminating partys notice requesting such breach to be remedied. No breach or violation of this agreement will cause this agreement or any license granted in it to terminate automatically or affect the definition of JFU.
7. Royalties
This agreement entitles the author to no royalties or other fees. To such extent as legally permissible, the author waives his or her right to collect royalties relative to the article in respect of any use of the article by JFU or its sublicensee.
8. Miscellaneous
JFU will publish the article (or have it published) in the journal if the articles editorial process is successfully completed and JFU or its sublicensee has become obligated to have the article published. JFU may conform the article to a style of punctuation, spelling, capitalization, referencing and usage that it deems appropriate. The author acknowledges that the article may be published so that it will be publicly accessible and such access will be free of charge for the readers.
